{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:20:17Z","timestamp":1792822817483,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000161","name":"National Institute of Standards and Technology","doi-asserted-by":"publisher","award":["70NANB21H105"],"award-info":[{"award-number":["70NANB21H105"]}],"id":[{"id":"10.13039\/100000161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI147870"],"award-info":[{"award-number":["R01AI147870"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI155150-01A1"],"award-info":[{"award-number":["1R01AI155150-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI174908"],"award-info":[{"award-number":["R01 AI174908"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01 AI162242"],"award-info":[{"award-number":["P01 AI162242"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IBX004525"],"award-info":[{"award-number":["IBX004525"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-005284"],"award-info":[{"award-number":["INV-005284"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-036842"],"award-info":[{"award-number":["INV-036842"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008510","name":"University of Maryland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006151","name":"Basic Energy Sciences","doi-asserted-by":"publisher","award":["DE-AC02-76SF00515"],"award-info":[{"award-number":["DE-AC02-76SF00515"]}],"id":[{"id":"10.13039\/100006151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006206","name":"Biological and Environmental Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Structure"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.str.2025.04.016","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T10:37:26Z","timestamp":1747219046000},"page":"1150-1164.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7798-3605","authenticated-orcid":false,"given":"Mohammad M.","family":"Sajadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolrahim","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Rikhtegaran","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Siska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutilio","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshitij","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Jumpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randal R.","family":"Ketchem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Tolbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Deming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Asakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Calvillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan D.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette","family":"Korber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan T.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia H.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Foulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parham","family":"Habibzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Aslanabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Hojabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Saadat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roza","family":"Zareidoodeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"K\u0119dzior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Pozharski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso","family":"Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hegang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Pazgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"DeVico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.str.2025.04.016_bib1","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/QAD.0b013e32835705dd","article-title":"Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens","volume":"26","author":"Bigoloni","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.str.2025.04.016_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw174","article-title":"Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s","volume":"3","author":"Dirajlal-Fargo","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.str.2025.04.016_bib3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/0956462416675107","article-title":"Integrase strand transfer inhibitor-associated diabetes mellitus: A case report","volume":"28","author":"Fong","year":"2017","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.str.2025.04.016_bib4","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkz224","article-title":"Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study","volume":"74","author":"Katlama","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.str.2025.04.016_bib5","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/QAD.0000000000003348","article-title":"Trends in diabetes incidence and associated risk factors among people living with HIV in the current treatment era","volume":"36","author":"Spieler","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.str.2025.04.016_bib6","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/cid\/ciac355","article-title":"Integrase Strand Transfer Inhibitors are Associated with Incident Diabetes Mellitus in People with HIV","volume":"75","author":"O'Halloran","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.str.2025.04.016_bib7","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2352-3018(23)00113-3","article-title":"Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2\/3 trial","volume":"10","author":"Ogbuagu","year":"2023","journal-title":"Lancet. HIV"},{"key":"10.1016\/j.str.2025.04.016_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1128\/JVI.01583-08","article-title":"Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies","volume":"83","author":"Doria-Rose","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib9","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.str.2025.04.016_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12517","article-title":"The quest for an antibody-based HIV vaccine","volume":"275","author":"Haynes","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.str.2025.04.016_bib12","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1128\/jvi.69.11.6609-6617.1995","article-title":"Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG","volume":"69","author":"Trkola","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib13","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.str.2025.04.016_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.immuni.2012.08.012","article-title":"Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies","volume":"37","author":"Kwong","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.str.2025.04.016_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature13601","article-title":"Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface","volume":"515","author":"Huang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.str.2025.04.016_bib16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.str.2025.04.016_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162694","article-title":"Human NK cells confer protection against HIV-1 infection in humanized mice","volume":"132","author":"Sungur","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.str.2025.04.016_bib18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.str.2025.04.016_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.str.2025.04.016_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh0004","article-title":"Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana","volume":"15","author":"Shapiro","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.str.2025.04.016_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","article-title":"Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity","volume":"26","author":"Niessl","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.str.2025.04.016_bib22","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","article-title":"Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial","volume":"30","author":"Julg","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.str.2025.04.016_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","article-title":"Prevention, treatment and cure of HIV infection","volume":"21","author":"Landovitz","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.str.2025.04.016_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26096","article-title":"Who prefers what? Correlates of preferences for next-generation HIV prevention products among a national U.S. sample of young men who have sex with men","volume":"26","author":"Biello","year":"2023","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.str.2025.04.016_bib25","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","article-title":"Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial","volume":"29","author":"Gunst","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.str.2025.04.016_bib26","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","article-title":"Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses","volume":"173","author":"Sajadi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.str.2025.04.016_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/infdis\/jiv448","article-title":"lambda Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies","volume":"213","author":"Sajadi","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.str.2025.04.016_bib28","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1128\/JVI.06547-11","article-title":"Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma","volume":"86","author":"Sajadi","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAI.0b013e3182100c1b","article-title":"Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity","volume":"57","author":"Sajadi","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.str.2025.04.016_bib30","doi-asserted-by":"crossref","first-page":"e00159-21","DOI":"10.1128\/JVI.00159-21","article-title":"Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement","volume":"95","author":"Liu","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1946918","article-title":"A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention","volume":"13","author":"Kwon","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.str.2025.04.016_bib32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41467-019-08658-4","article-title":"Improvement of antibody functionality by structure-guided paratope engraftment","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.str.2025.04.016_bib33","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nsmb.3382","article-title":"Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer","volume":"24","author":"Liu","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.str.2025.04.016_bib34","doi-asserted-by":"crossref","first-page":"W213","DOI":"10.1093\/nar\/gkv404","article-title":"CATNAP: a tool to compile, analyze and tally neutralizing antibody panels","volume":"43","author":"Yoon","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.str.2025.04.016_bib35","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.2649","article-title":"A quantitative basis for antiretroviral therapy for HIV-1 infection","volume":"18","author":"Jilek","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.str.2025.04.016_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection","volume":"12","author":"Wagh","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.str.2025.04.016_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006860","article-title":"Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections","volume":"14","author":"Wagh","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.str.2025.04.016_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734110","article-title":"Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth","volume":"12","author":"van Dorsten","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.str.2025.04.016_bib39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/COH.0000000000000800","article-title":"Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage","volume":"18","author":"Wagh","year":"2023","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.str.2025.04.016_bib40","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.celrep.2018.04.101","article-title":"Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity","volume":"23","author":"Prigent","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.str.2025.04.016_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12977-018-0435-0","article-title":"Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design","volume":"15","author":"Finney","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.str.2025.04.016_bib42","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.str.2025.04.016_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16050594","article-title":"Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV","volume":"16","author":"Mayer","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.str.2025.04.016_bib44","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/19420862.2016.1193660","article-title":"Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies","volume":"8","author":"Avery","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.str.2025.04.016_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.str.2025.04.016_bib46","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41590-023-01741-5","article-title":"Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells","volume":"25","author":"Board","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.str.2025.04.016_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/v15020365","article-title":"Human Hematopoietic Stem Cell Engrafted IL-15 Transgenic NSG Mice Support Robust NK Cell Responses and Sustained HIV-1 Infection","volume":"15","author":"Abeynaike","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.str.2025.04.016_bib48","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1073\/pnas.1018360108","article-title":"Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance","volume":"108","author":"Sampah","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.str.2025.04.016_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.str.2025.04.016_bib50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0022-5193(76)90169-7","article-title":"Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands","volume":"59","author":"Chou","year":"1976","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.str.2025.04.016_bib51","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.str.2025.04.016_bib52","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.str.2025.04.016_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01274-21","article-title":"Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer","volume":"12","author":"Tolbert","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.str.2025.04.016_bib54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.immuni.2013.04.012","article-title":"Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies","volume":"39","author":"Zhou","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.str.2025.04.016_bib55","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.str.2025.04.016_bib56","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","article-title":"Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization","volume":"153","author":"Klein","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.str.2025.04.016_bib57","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1128\/JVI.07163-11","article-title":"Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib58","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.str.2025.04.016_bib59","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib60","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1128\/JVI.03246-15","article-title":"Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design","volume":"90","author":"Kwon","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib61","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1073\/pnas.1810576116","article-title":"Five computational developability guidelines for therapeutic antibody profiling","volume":"116","author":"Raybould","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.str.2025.04.016_bib62","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41592-020-0848-2","article-title":"Macromolecular modeling and design in Rosetta: recent methods and frameworks","volume":"17","author":"Leman","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.str.2025.04.016_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1836719","article-title":"Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies","volume":"12","author":"Chuang","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.str.2025.04.016_bib64","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1743053","article-title":"Predicting Antibody Developability Profiles Through Early Stage Discovery Screening","volume":"12","author":"Bailly","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.str.2025.04.016_bib65","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2185924","article-title":"Blueprint for antibody biologics developability","volume":"15","author":"Mieczkowski","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.str.2025.04.016_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/antib8040055","article-title":"Antibody Structure and Function: The Basis for Engineering Therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.str.2025.04.016_bib67","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.str.2025.04.016_bib68","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1128\/JVI.00754-11","article-title":"Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01","volume":"85","author":"Li","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib69","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4049\/jimmunol.1302515","article-title":"Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline","volume":"192","author":"Georgiev","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.str.2025.04.016_bib70","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2015.05.007","article-title":"Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors","volume":"161","author":"Zhou","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.str.2025.04.016_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209034","article-title":"Improved multilineage human hematopoietic reconstitution and function in NSGS mice","volume":"13","author":"Wunderlich","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.str.2025.04.016_bib72","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/scd.2016.0083","article-title":"Comparison of Human Hematopoietic Reconstitution in Different Strains of Immunodeficient Mice","volume":"26","author":"Beyer","year":"2017","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.str.2025.04.016_bib73","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200045R","article-title":"Enhanced development of functional human NK cells in NOD-scid-IL2rg(null) mice expressing human IL15","volume":"36","author":"Aryee","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.str.2025.04.016_bib74","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fimmu.2019.01512","article-title":"Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure","volume":"10","author":"Ray","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.str.2025.04.016_bib75","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/JVI.03136-14","article-title":"Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes","volume":"89","author":"Kong","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib76","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1038\/s41467-024-51656-4","article-title":"Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted\/founder sensitivity to broadly neutralizing antibodies","volume":"15","author":"Parthasarathy","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.str.2025.04.016_bib77","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1107\/S0021889800018227","article-title":"Global indicators of X-ray data quality","volume":"34","author":"Weiss","year":"2001","journal-title":"J. Appl. Cryst."},{"key":"10.1016\/j.str.2025.04.016_bib78","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1126\/science.1218231","article-title":"Linking crystallographic model and data quality","volume":"336","author":"Karplus","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.str.2025.04.016_bib79","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0076-6879(97)77021-6","article-title":"Free R value: Cross-validation in crystallography","author":"Brunger","year":"1997"},{"key":"10.1016\/j.str.2025.04.016_bib80","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.str.2025.04.016_bib81","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1128\/JVI.02108-09","article-title":"Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies","volume":"84","author":"Seaman","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib82","doi-asserted-by":"crossref","first-page":"11427","DOI":"10.1128\/JVI.74.24.11427-11436.2000","article-title":"Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex","volume":"74","author":"Fouts","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.str.2025.04.016_bib84","doi-asserted-by":"crossref","first-page":"12895","DOI":"10.1128\/JVI.02194-14","article-title":"Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection","volume":"88","author":"Acharya","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib85","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1128\/JCM.41.10.4531-4536.2003","article-title":"New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma","volume":"41","author":"Palmer","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.str.2025.04.016_bib86","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2025.04.016_bib87","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1107\/S0907444902016657","article-title":"PHENIX: building new software for automated crystallographic structure determination","volume":"58","author":"Adams","year":"2002","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2025.04.016_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.str.2025.04.016_bib89","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.1073\/pnas.1217609110","article-title":"Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding","volume":"110","author":"Guan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.str.2025.04.016_bib90","doi-asserted-by":"crossref","first-page":"W375","DOI":"10.1093\/nar\/gkm216","article-title":"MolProbity: all-atom contacts and structure validation for proteins and nucleic acids","volume":"35","author":"Davis","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.str.2025.04.016_bib91","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1107\/S0907444994003112","article-title":"The CCP4 suite: programs for protein crystallography","volume":"50","year":"1994","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2025.04.016_bib92","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.str.2025.04.016_bib93","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2172-12-33","article-title":"LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays","volume":"12","author":"Piehler","year":"2011","journal-title":"BMC Immunol."},{"key":"10.1016\/j.str.2025.04.016_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2010.08.028","article-title":"Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC","volume":"408","author":"Edmonds","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.str.2025.04.016_bib95","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1128\/JVI.00156-14","article-title":"HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities","volume":"88","author":"Pollara","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2025.04.016_bib96","article-title":"AI-based antibody discovery platform identifies novel, diverse and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains","author":"Moldovan Loomis","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.str.2025.04.016_bib97","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.xphs.2019.07.009","article-title":"Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity","volume":"109","author":"Kerwin","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.str.2025.04.016_bib98","series-title":"High Throughput Interrogation of Physiochemical Properties of a Protein","author":"Gillespie","year":"2022"},{"key":"10.1016\/j.str.2025.04.016_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ab.2018.08.027","article-title":"Adapting the chemical unfolding assay for high-throughput protein screening using experimental and spectroscopic corrections","volume":"563","author":"Floyd","year":"2018","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.str.2025.04.016_bib100","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.xphs.2016.05.021","article-title":"A Micro-Polyethylene Glycol Precipitation Assay as a Relative Solubility Screening Tool for Monoclonal Antibody Design and Formulation Development","volume":"105","author":"Toprani","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.str.2025.04.016_bib101","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4161\/mabs.27431","article-title":"High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy","volume":"6","author":"Liu","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.str.2025.04.016_bib102","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/19420862.2015.1048410","article-title":"A novel screening method to assess developability of antibody-like molecules","volume":"7","author":"Kohli","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.str.2025.04.016_bib103","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.str.2025.04.016_bib104","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12575-017-0060-7","article-title":"Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells","volume":"19","author":"Fang","year":"2017","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.str.2025.04.016_bib105","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.immuni.2015.11.007","article-title":"Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans","volume":"43","author":"Garces","year":"2015","journal-title":"Immunity"}],"container-title":["Structure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969212625001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969212625001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:43:53Z","timestamp":1786218233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969212625001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":105,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0969212625001509"],"URL":"https:\/\/doi.org\/10.1016\/j.str.2025.04.016","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.14.618178","asserted-by":"object"}]},"ISSN":["0969-2126"],"issn-type":[{"value":"0969-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV","name":"articletitle","label":"Article Title"},{"value":"Structure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.str.2025.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}